Clinical Edge Journal Scan

Cardiovascular disease: The leading cause of noncancer death in CRC


 

Key clinical point: Cardiovascular disease (CVD) is the most common cause of noncancer death among patients with colorectal cancer (CRC).

Major finding: During a median follow-up of 37 months, 79,455 patient deaths occurred, of which 23,270 (29.29%) were attributed to causes other than CRC, such as CVD (9702 [41.69%] of 23,270 deaths). The 1-, 3-, and 5-year cumulative incidence functions of CVD deaths were 12.20%, 24.25%, and 30.51%, respectively, whereas those of non-CVD deaths were 1.93%, 4.13%, and 4.77%, respectively.

Study details: This real-world, retrospective study included 197,699 patients with CRC and active follow-up data, including mortality causes, from 18 Surveillance, Epidemiology, and End Results (SEER) registries.

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Zhang S et al. Cardiovascular outcomes in the patients with colorectal cancer: A multi-registry-based cohort study of 197,699 cases in the real world. Front Cardiovasc Med. 2022;9:851833 (Jun 16). Doi: 10.3389/fcvm.2022.851833

Recommended Reading

Marital status plays modest role in gastric cancer overall survival
MDedge Hematology and Oncology
Life-threatening adverse events in liver cancer less frequent with ICI therapy
MDedge Hematology and Oncology
Barrett’s esophagus: AGA screening update ‘goes above and beyond’
MDedge Hematology and Oncology
Stage II colon cancer: ctDNA-guided approach reduces adjuvant chemotherapy use without compromising recurrence risk
MDedge Hematology and Oncology
Link between Western diet, intestinal microbiota, and CRC: Findings from 2 U.S. cohort studies
MDedge Hematology and Oncology
Stage II/III CRC: 3-month oxaliplatin with 6-month fluoropyrimidine, a promising adjuvant treatment
MDedge Hematology and Oncology
FOLFIRI-bevacizumab tops FOLFIRI-aflibercept in treating metastatic CRC after FOLFOX-bevacizumab failure
MDedge Hematology and Oncology
Efficacy of colonoscopy for preventing CRC remains unaffected by location
MDedge Hematology and Oncology
Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy confers survival benefit in CRC peritoneal metastasis
MDedge Hematology and Oncology
CRC: Colonoscopy offers a survival benefit over fecal immunochemical test
MDedge Hematology and Oncology